Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon

Hepatology Research

Volumn 42, Issue 11, 2012, Pages 1089-1099

  Sugiyama, Masaya ^a   Kimura, Tatsuji ^b   Naito, Shigeko ^b   Mukaide, Motokazu ^a,c   Shinauchi, Takanori ^b   Ueno, Masakatsu ^b   Ito, Kiyoaki ^a   Murata, Kazumoto ^a   Mizokami, Masashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Institute of Immunology Co Ltd   (Japan)

^c SRL INC   (Japan)

Author keywords

interferon; Chemiluminescence enzyme immunoassay; Enzyme linked immunoassay; Interleukin 28B

Indexed keywords

COMPLEMENTARY DNA; INTERFERON; LAMBDA 3 INTERFERON; PEGINTERFERON ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CHEMOLUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE PROBE; HEMATOPOIETIC CELL; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOASSAY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84868006724     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01032.x     Document Type: Article

References (36)

1. Kotenko SV, Gallagher G, Baurin VV etal. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
2. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
3. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-31.
4. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-75.
5. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-9.
6. Onoguchi K, Yoneyama M, Takemura A etal. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 7576-81.
7. Yang K, Puel A, Zhang S etal. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005; 23: 465-78.
8. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
9. Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. Novel findings for the development of drug therapy for various liver diseases: genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C. J Pharmacol Sci 2011; 115: 263-9.
10. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45, 45 e1-7.
12. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
13. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
14. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
15. Diegelmann J, Beigel F, Zitzmann K etal. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010; 5: e15200.
16. Langhans B, Kupfer B, Braunschweiger I etal. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-65.
17. Stoltz M, Ahlm C, Lundkvist A, Klingstrom J. Lambda interferon (IFN-lambda) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production. J Virol 2007; 81: 8685-91.
18. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS ONE 2011; 6: e26620.
19. Kimura M, Tatsumi KI, Tada H etal. Anti-CYP2D6 antibodies detected by quantitative radioligand assay and relation to antibodies to liver-specific arginase in patients with autoimmune hepatitis. Clin Chim Acta 2002; 316: 155-64.
20. Yoshitake S, Imagawa M, Ishikawa E etal. Mild and efficient conjugation of rabbit Fab' and horseradish peroxidase using a maleimide compound and its use for enzyme immunoassay. J Biochem 1982; 92: 1413-24.
21. Ank N, Iversen MB, Bartholdy C etal. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-85.
22. Osterlund P, Veckman V, Siren J etal. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005; 79: 9608-17.
23. Urban TJ, Thompson AJ, Bradrick SS etal. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.
24. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417-23.
25. Schlee M, Roth A, Hornung V etal. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009; 31: 25-34.
26. Kato H, Takeuchi O, Sato S etal. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-5.
27. Adolf GR, Swetly P. Interferon production in human hematopoietic cell lines: response to chemicals and characterization of interferons. J Interferon Res 1982; 2: 261-70.
28. Takakuwa T, Luo WJ, Ham MF, Sakane-Ishikawa F, Wada N, Aozasa K. Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression. Am J Pathol 2004; 164: 967-74.
29. Anvret M, Karlsson A, Bjursell G. Evidence for integrated EBV genomes in Raji cellular DNA. Nucleic Acids Res 1984; 12: 1149-61.
30. Iwakiri D, Zhou L, Samanta M etal. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206: 2091-9.
31. van Gent M, Griffin BD, Berkhoff EG etal. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J Immunol 2011; 186: 1694-702.
32. Fiola S, Gosselin D, Takada K, Gosselin J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 2010; 185: 3620-31.
33. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol 2009; 182: 851-9.
34. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 1979; 149: 969-74.
35. Gallagher R, Collins S, Trujillo J etal. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-33.
36. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007; 179: 3434-42.